cotrimoxazol (trimethoprim +sulfamethoxazol)
Safety margins
Weight | ROA | Dosage |
---|---|---|
ROA: po |
Dosage: min. 80/400mg 1 dd to max. 320/1600mg 3 dd |
|
ROA: iv |
Dosage: min. 80/400mg 1 dd to max. 320/1600mg 3 dd |
Dosage for "I" sensitivity
Weight | ROA | Load | Dosage |
---|---|---|---|
ROA: po |
Load: - |
Dosage: 240/1200mg 2 dd |
|
ROA: iv |
Load: - |
Dosage: 240/1200mg 2 dd |
Kidney function
ROA | GFR | Dosage | Interval | Comments |
---|---|---|---|---|
ROA: po | ||||
GFR: 10 - 30 |
Dosage: 50% |
Interval: 12 Hours |
Comments: eerste dag de standaarddosering van 960 mg 2x per dag |
|
GFR: <10 |
Dosage: do not prescribe |
|||
ROA: iv | ||||
GFR: 10 - 30 |
Dosage: 50% |
Interval: 12 Hours |
Comments: eerste dag de standaarddosering van 960 mg 2x per dag |
|
GFR: <10 |
Dosage: do not prescribe |
Notes GFR general:
Renal function-replacement therapy
CAPD: eerste dag de standaarddosering van 960 mg 2x per dag, vervolgens onderhoudsdosering 480 mg 2x per dag of 960 mg 1x per dag. Bij PCP: zie boven. Monitor de N4-acetylmetaboliet.
Hemo dialysis: eerste dag de standaarddosering van 960 mg 2x per dag, vervolgens onderhoudsdosering 480 mg 2x per dag of 960 mg 1x per dag. Bij PCP: zie boven. Monitor de N4-acetylmetaboliet.
CAV / VVHD: eerste dag de standaarddosering van 960 mg 2x per dag, vervolgens 480 mg 2dd of 960 mg 1dd. Behandeling PCP: eerste 3 dagen 1920 mg 3x per dag, daarna 1920 mg 2x per dag, volg plasmapiegel. Profylaxe PCP: zie boven. Monitor N4-acetylmetaboliet.
Interactions
Interaction with (ATC): | Expected effect: |
---|---|
Interaction with (ATC): L04AD01 - Ciclosporin |
Expected effect: verlaging ciclosporineconcentratie in volbloed en verhoogde kans op nefrotoxiciteit |
Interaction with (ATC): N03AB02 - Phenytoin |
Expected effect: verhoging plasmaconcentratie fenytoine |
Interaction with (ATC): B03BB01 - Folic Acid |
Expected effect: vermindering werking foliumzuur |
Interaction with (ATC): L01BA01 - Methotrexate |
Expected effect: verhoging plasmaconcentratie methotrexaat |
Interaction with (ATC): B01AA - Vitamin K Antagonists |
Expected effect: versterking effect orale anticoagulantia |
Pregnancy
Due to the expiration of the alphanumeric classification for use in pregnancy and lactation, reference is made to the current, online information of the Teratology Information Service (TIS) of LAREB:
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Zwangerschap#TOC_Middelen_bij6
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Borstvoeding#TOC_Middelen_bij16
Metadata
Swab vid: M-1291.8
Updated: 02/15/2024 - 16:16
Status: Published